|
Dr. Dunsire joined Millennium in July, 2005 with nearly 20 years of experience in the commercial, operational, clinical and scientific aspects of a world-leading pharmaceutical business.
Dr. Dunsire led the Novartis U.S. Oncology Business, playing a critical role in the broad development and successful launch of a number of products including Zometa, Femara and Gleevec.
She was also responsible for managing the merger and significant growth of the combined Sandoz Pharmaceuticals and Ciba-Geigy oncology businesses and evaluated and implemented key business development initiatives. Dr. Dunsire also served on the U.S. pharmaceutical executive committee at Novartis, was a designated member of the corporate executive group, and a member of the operating committee charged with defining corporate strategy, managing operations and assessing executive performance. Dr. Dunsire is currently a board member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Earlier in her career, Dr. Dunsire was a clinical researcher responsible for the implementation of global phase II and phase III studies across multiple therapeutic areas such as immunology, endocrinology, neurology, dermatology, oncology and transplantation. She has also been a practicing physician.
Dr. Dunsire was the 2001 recipient of the American Cancer Society Excalibur Award and the 2000 recipient of the Health Care Business Women's Association Rising Star Award. Dr. Dunsire is a graduate of the medical school of the University of the Witwatersrand, South Africa. | 